Company / Accounts Receivable
Amneal Pharmaceuticals, Inc. Accounts Receivable History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$741.8M
FY2022
5-year range
$662.6M / $741.8M
FY2018-FY2022
Trend
+12.0%
vs FY2021
Sector context
#22 of 113
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s accounts receivable of $742M is higher than 81% of companies in the Health Care sector (FY2022). Accounts Receivable has increased for 5 consecutive years, from $351M in FY2017 to $742M in FY2022.
Based on SEC 10-K filings.
$742M in FY2022 with a 5-year CAGR of +16.1%. Top quartile in the Health Care sector.
Improved from $639M to $742M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +7.1%
- 5-Year CAGR
- +16.1%
- 10-Year CAGR
- -
Sector benchmark
-34.8% below sector average
Key checks
Key Insights
- Amneal Pharmaceuticals, Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +16.1%, indicating consistent growth.
- In FY2022, accounts receivable increased 12.0% year-over-year.
- Ranks #22 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $741.8M | +12.0% |
| FY2021 | $662.6M | +3.7% |
| FY2020 | $638.9M | +5.7% |
| FY2019 | $604.4M | +25.5% |
| FY2018 | $481.5M | +37.0% |
| FY2017 | $351.4M | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026